Nature Communications (Aug 2022)
Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer
- Nader Al-Nakouzi,
- Chris Kedong Wang,
- Htoo Zarni Oo,
- Irina Nelepcu,
- Nada Lallous,
- Charlotte B. Spliid,
- Nastaran Khazamipour,
- Joey Lo,
- Sarah Truong,
- Colin Collins,
- Desmond Hui,
- Shaghayegh Esfandnia,
- Hans Adomat,
- Thomas Mandel Clausen,
- Tobias Gustavsson,
- Swati Choudhary,
- Robert Dagil,
- Eva Corey,
- Yuzhuo Wang,
- Anne Chauchereau,
- Ladan Fazli,
- Jeffrey D. Esko,
- Ali Salanti,
- Peter S. Nelson,
- Martin E. Gleave,
- Mads Daugaard
Affiliations
- Nader Al-Nakouzi
- Department of Urologic Sciences, University of British Columbia
- Chris Kedong Wang
- Department of Urologic Sciences, University of British Columbia
- Htoo Zarni Oo
- Department of Urologic Sciences, University of British Columbia
- Irina Nelepcu
- Department of Urologic Sciences, University of British Columbia
- Nada Lallous
- Department of Urologic Sciences, University of British Columbia
- Charlotte B. Spliid
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital
- Nastaran Khazamipour
- Department of Urologic Sciences, University of British Columbia
- Joey Lo
- Department of Urologic Sciences, University of British Columbia
- Sarah Truong
- Department of Urologic Sciences, University of British Columbia
- Colin Collins
- Department of Urologic Sciences, University of British Columbia
- Desmond Hui
- Vancouver Prostate Centre
- Shaghayegh Esfandnia
- Vancouver Prostate Centre
- Hans Adomat
- Vancouver Prostate Centre
- Thomas Mandel Clausen
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital
- Tobias Gustavsson
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital
- Swati Choudhary
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital
- Robert Dagil
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital
- Eva Corey
- Department of Urology, University of Washington
- Yuzhuo Wang
- Department of Urologic Sciences, University of British Columbia
- Anne Chauchereau
- Prostate Cancer Group, INSERM UMR981, Gustave Roussy, University of Paris-Saclay
- Ladan Fazli
- Department of Urologic Sciences, University of British Columbia
- Jeffrey D. Esko
- Department of Cellular and Molecular Medicine, University of California San Diego
- Ali Salanti
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital
- Peter S. Nelson
- Department of Urology, University of Washington
- Martin E. Gleave
- Department of Urologic Sciences, University of British Columbia
- Mads Daugaard
- Department of Urologic Sciences, University of British Columbia
- DOI
- https://doi.org/10.1038/s41467-022-32530-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Chondroitin sulfate (CS) is one of the most abundant glycosaminoglycans in prostate cancers. Here the authors show that inhibition of the androgen receptor pathway leads to the upregulation of CS, which promotes prostate cancer growth and metastasis.
